Millipore Sigma Vibrant Logo

341607 FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7 - Calbiochem

The FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 controls the biological activity of FGF/VEGF Receptor Tyrosine Kinase. Primarily used for Phosphorylation & Dephosphorylation applications.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX

View Products on Sigmaaldrich.com
341607
Voir les Prix & la Disponibilité

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
219580-11-7C₂₈H₄₁N₇O₃

Prix & Disponibilité

Référence DisponibilitéConditionnement Qté Prix Quantité
341607-5MG
Récupération des données relatives à la disponibilité...
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

      		 Ampoule plast. 5 mg
      Prix en cours de récupération
      Le prix n'a pas pu être récupéré
      La quantité minimale doit être un multiple de
      Maximum Quantity is
      À la validation de la commande Plus d'informations
      Vous avez sauvegardé ()
       
      —
      Demander le prix
      		 —
      Description
      OverviewA cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.
      Catalogue Number341607
      Brand Family Calbiochem®
      Synonyms1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX
      References
      ReferencesKoziczak, M., et al. 2004. Oncogene 23, 3501.
      Trudel, S., et al. 2004. Blood 103, 3521.
      Skaper, S.D., et al. 2000. J. Neurochem. 75, 1520.
      Mohammadi, M., et al. 1998. EMBO J. 17, 5896.
      Product Information
      CAS number219580-11-7
      FormYellow solid
      Hill FormulaC₂₈H₄₁N₇O₃
      Chemical formulaC₂₈H₄₁N₇O₃
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥97% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Irritant
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      341607-5MG 04055977195200

      Documentation

      FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7 - Calbiochem FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 - CAS 219580-11-7 - Calbiochem Certificats d'analyse

      TitreNuméro de lot
      341607

      Références bibliographiques

      Aperçu de la référence bibliographique
      Koziczak, M., et al. 2004. Oncogene 23, 3501.
      Trudel, S., et al. 2004. Blood 103, 3521.
      Skaper, S.D., et al. 2000. J. Neurochem. 75, 1520.
      Mohammadi, M., et al. 1998. EMBO J. 17, 5896.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision04-May-2011 RFH
      Synonyms1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX
      DescriptionA cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number219580-11-7
      Chemical formulaC₂₈H₄₁N₇O₃
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Irritant
      ReferencesKoziczak, M., et al. 2004. Oncogene 23, 3501.
      Trudel, S., et al. 2004. Blood 103, 3521.
      Skaper, S.D., et al. 2000. J. Neurochem. 75, 1520.
      Mohammadi, M., et al. 1998. EMBO J. 17, 5896.